SK bioscience Co.,Ltd. (KRX:302440)

SK bioscience Statistics

Total Valuation

SK bioscience has a market cap or net worth of KRW 4.26 trillion. The enterprise value is 3.80 trillion.

Market Cap	4.26T
Enterprise Value	3.80T

Important Dates

The next estimated earnings date is Friday, October 31, 2025.

Earnings Date	Oct 31, 2025
Ex-Dividend Date	n/a

Share Statistics

SK bioscience has 78.37 million shares outstanding. The number of shares has increased by 1.35% in one year.

Current Share Class	78.37M
Shares Outstanding	78.37M
Shares Change (YoY)	+1.35%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	2.81%
Float	25.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.97
PB Ratio	2.11
P/TBV Ratio	2.54
P/FCF Ratio	n/a
P/OCF Ratio	2,435.68
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-72.13
EV / Sales	7.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-20.44

Financial Position

The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.20.

Current Ratio	4.48
Quick Ratio	3.83
Debt / Equity	0.20
Debt / EBITDA	n/a
Debt / FCF	-2.16
Interest Coverage	-18.14

Financial Efficiency

Return on equity (ROE) is -2.44% and return on invested capital (ROIC) is -4.19%.

Return on Equity (ROE)	-2.44%
Return on Assets (ROA)	-3.71%
Return on Invested Capital (ROIC)	-4.19%
Return on Capital Employed (ROCE)	-5.64%
Revenue Per Employee	583.33M
Profits Per Employee	-57.47M
Employee Count	917
Asset Turnover	0.22
Inventory Turnover	3.01

Taxes

Income Tax	-55.52B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.02% in the last 52 weeks. The beta is 1.16, so SK bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.16
52-Week Price Change	+4.02%
50-Day Moving Average	48,463.00
200-Day Moving Average	45,824.25
Relative Strength Index (RSI)	72.43
Average Volume (20 Days)	135,873

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK bioscience had revenue of KRW 534.91 billion and -52.70 billion in losses. Loss per share was -676.46.

Revenue	534.91B
Gross Profit	44.58B
Operating Income	-142.91B
Pretax Income	-101.37B
Net Income	-52.70B
EBITDA	-69.20B
EBIT	-142.91B
Loss Per Share	-676.46

Balance Sheet

The company has 1.10 trillion in cash and 402.11 billion in debt, giving a net cash position of 694.66 billion or 8,863.96 per share.

Cash & Cash Equivalents	1.10T
Total Debt	402.11B
Net Cash	694.66B
Net Cash Per Share	8,863.96
Equity (Book Value)	2.02T
Book Value Per Share	22,869.85
Working Capital	1.12T

Cash Flow

In the last 12 months, operating cash flow was 1.75 billion and capital expenditures -187.69 billion, giving a free cash flow of -185.94 billion.

Operating Cash Flow	1.75B
Capital Expenditures	-187.69B
Free Cash Flow	-185.94B
FCF Per Share	-2,372.56

Margins

Gross margin is 8.33%, with operating and profit margins of -26.72% and -9.85%.

Gross Margin	8.33%
Operating Margin	-26.72%
Pretax Margin	-18.95%
Profit Margin	-9.85%
EBITDA Margin	-12.94%
EBIT Margin	-26.72%
FCF Margin	n/a

Dividends & Yields

SK bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.35%
Shareholder Yield	-1.35%
Earnings Yield	-1.24%
FCF Yield	-4.36%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK bioscience has an Altman Z-Score of 3.48 and a Piotroski F-Score of 3.

Altman Z-Score	3.48
Piotroski F-Score	3